Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mirvetuximab soravtansine-gynx + olaparib
- Development stage
- Phase 2
- Lead developer
- AbbVie
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This combination therapy consists of mirvetuximab soravtansine-gynx and olaparib. Mirvetuximab soravtansine-gynx (Elahere) is a first-in-class antibody-drug conjugate (ADC) targeting folate receptor alpha (FRα), which is highly expressed in many epithelial ovarian cancers. It comprises an FRα-binding antibody linked to the potent microtubule-disrupting agent DM4. Olaparib (Lynparza) is a small molecule inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, including PARP1, PARP2, and PARP3, which play a critical role in DNA damage repair. The combination is being investigated by the University of Colorado, Denver, as a maintenance therapy for patients with recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer. The therapeutic rationale involves the synergistic effect of targeted cytotoxic delivery via the ADC and the inhibition of DNA repair mechanisms by the PARP inhibitor, potentially overcoming resistance and improving outcomes in FRα-expressing tumors.
- Other names
- mirvetuximab soravtansineMIRVmirvetuximab soravtansine-gynx
02
Targets
FOLR1 (FRα)PARP1 (Poly (adp-ribose) polymerase 1)PARP2 (Poly (adp-ribose) polymerase 2)PARP3 (Poly(adp-ribose) polymerase 3)
Beyond the preview
Go deeper on mirvetuximab soravtansine-gynx + olaparib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mirvetuximab soravtansine-gynx + olaparib.